Name: A NEW ERA IN TREATING HEMOPHILIA A AND B
Start: 2016-04-14T12:15:00-05:00
End: 2016-04-14T13:45:00-05:00
Location: Sheraton Chicago Hotel & Towers

A NEW ERA IN TREATING HEMOPHILIA A AND B

HemoAB Symposium

<DIV CLASS="infoHeader"><SPAN>OVERVIEW</SPAN></DIV>
<DIV CLASS="infoText"><SPAN>The recent introduction of new bioengineered Factor VIII and Factor IX replacement therapies with longer half-lives are expected to have profound implications on prophylaxis treatment regimens on patients being treated for hemophilia. The decreased frequency of infusions with these bioengineered therapies is expected to facilitate individualized treatment plans that will incorporate patient-specific targeted trough levels, reducing risk of breakthrough bleeds. Prophylaxis can protect against joint disease and allow a hemophilia patient to live a normal life with an average life expectancy, but the key to its effectiveness is early implementation and good adherence. This live educational activity will review the principles of pharmacokinetic-based factor replacement therapy, including its potential advantages and disadvantages as prophylaxis versus on-demand therapy. Because adherence is the cornerstone of effective prophylaxis, effective methods to measure and increase adherence that can be practically implemented in a busy clinical setting will be discussed. </SPAN></DIV>
<DIV CLASS="infoText"><BR></DIV>
<DIV CLASS="infoText"><BR></DIV>
<DIV CLASS="infoText"><SPAN>GOAL</SPAN></DIV>
<DIV CLASS="infoText"><SPAN>This live case-based educational activity will provide clinicians who treat patients with hemophilia A or B with up-to-date information on pharmacokinetic-based factor replacement when used as prophylaxis and, because prophylaxis relies on optimal adherence, practical methods to measure and address adherence issues.</SPAN></DIV>
<DIV CLASS="infoText"><BR></DIV>
<DIV CLASS="infoText"><BR></DIV>
<DIV CLASS="infoText"><SPAN>INTENDED AUDIENCE</SPAN></DIV>
<DIV CLASS="infoText"><SPAN>This activity has been designed to meet the needs of adult and pediatric physicians in hematology settings, as well as other appropriate healthcare providers (including orthopedists, dentists, nurse practitioners and physicians’ assistants) who care for patients with hemophilia. There are no prerequisites.</SPAN></DIV>
<DIV CLASS="infoText"><BR></DIV>
<DIV CLASS="infoText"><BR></DIV>
<DIV CLASS="infoText"><SPAN>LEARNING OBJECTIVES</SPAN></DIV>
<DIV CLASS="infoText"><SPAN><SPAN>After participating in this activity, the participant will demonstrate the ability to:<BR></SPAN></SPAN>
<UL>
<LI><STRONG>DESCRIBE </STRONG> the role of pharmacokinetic-based therapy in the management of children and adults with hemophilia.</LI>
<LI><STRONG>IMPLEMENT </STRONG> PK-based therapy for patients with hemophilia.</LI>
<LI><STRONG>DESCRIBE </STRONG> clinician interventions to identify and address medication nonadherence in the management of patients with hemophilia.</LI>
<LI><STRONG>INCORPORATE </STRONG> rapid methods to measure adherence to therapy in the management of patients of hemophilia.</LI>
</UL>
<SPAN>The Johns Hopkins University School of Medicine takes responsibility for the content, quality, and scientific integrity of this CME activity.<BR><BR></SPAN></DIV>
<DIV CLASS="infoHeader"><SPAN>ACCREDITATION STATEMENT</SPAN></DIV>
<DIV CLASS="infoText"><SPAN>The Johns Hopkins University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.</SPAN></DIV>
<DIV CLASS="infoText"><BR></DIV>
<DIV CLASS="infoText"><SPAN>CREDIT DESIGNATION STATEMENT</SPAN></DIV>
<DIV CLASS="infoText"><SPAN>The Johns Hopkins University School of Medicine designates this live activity for a maximum of 1.5 <I>AMA PRA Category 1 Credit(s)</I>TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.</SPAN></DIV>
<DIV CLASS="infoText"><BR></DIV>
<DIV CLASS="infoText"><BR></DIV>
<DIV CLASS="infoText"><SPAN>AGENDA</SPAN></DIV>
<DIV CLASS="infoText"><SPAN><SPAN>12:15 – 12:25 PM   Conference Goals and Preassessment<BR><I>                                    John J. Strouse, MD, PhD</I></SPAN></SPAN></DIV>
<DIV CLASS="infoText"><SPAN><SPAN>12:25 – 12:55 PM   Pharmacokinetic Based Factor Replacement to Optimize Prophylactic and </SPAN></SPAN></DIV>
<DIV CLASS="infoText"><SPAN><SPAN><SPAN><SPAN><I>                                    </I></SPAN></SPAN>Therapeutic Treatment of Hemophilia<BR><I><SPAN><SPAN><I>                                    </I></SPAN></SPAN>Stacy E. Croteau, MD, MMS</I></SPAN></SPAN></DIV>
<DIV CLASS="infoText"><SPAN><SPAN>12:55 – 1:25 PM    Clinician Interventions to Improve Adherence to Hemophilia Treatment<BR><I><SPAN><SPAN><I>                                    </I></SPAN></SPAN>Michelle N. Eakin, PhD </I></SPAN></SPAN></DIV>
<DIV CLASS="infoText"><SPAN><SPAN>1:25 – 1:45 PM      Q & A and Educational Outcomes Activity <BR><I><SPAN><SPAN><I>                                    </I></SPAN></SPAN>John J. Strouse, MD, PhD</I></SPAN></SPAN>
<P><I>This schedule is subject to change. </I></P>
<P><BR></P>
</DIV>
<DIV CLASS="infoHeader"><SPAN>PARTICIPATING FACULTY</SPAN></DIV>
<DIV CLASS="infoText"><SPAN><STRONG>John J. Strouse, MD, PhD (Course Director)</STRONG></SPAN><BR><SPAN>Assistant Professor of Pediatrics and Medicine<BR>Johns Hopkins University School of Medicine<BR>Division of Pediatric Hematology<BR>Baltimore, Maryland<BR><BR><SPAN><STRONG>Stacy E. Croteau, MD, MMS</STRONG></SPAN><BR>Instructor in Pediatrics<BR>Harvard Medical School<BR>Associate Director<BR>Boston Hemophilia Center<BR>Boston, Massachusetts<BR><BR><SPAN><STRONG>Michelle N. Eakin, PhD</STRONG></SPAN><BR>Assistant Professor<BR>Division of Pulmonary and Critical Care Medicine<BR>Johns Hopkins University School of Medicine <BR>Baltimore, Maryland<BR><BR></SPAN></DIV>
<DIV CLASS="infoHeader"><SPAN>POLICY ON FACULTY AND PROVIDER DISCLOSURE</SPAN></DIV>
<DIV CLASS="infoText"><SPAN>It is the policy of the Johns Hopkins University School of Medicine that the faculty and provider disclose real or apparent conflicts of interest relating to the topics of this educational activity, and also disclose discussions of unlabeled/unapproved uses of drugs or devices during their presentation(s). Johns Hopkins University School of Medicine OCME has established policies in place that will identify and resolve all conflicts of interest prior to this educational activity. Detailed disclosures will be made in the course materials.</SPAN></DIV>
<DIV CLASS="infoText"><BR></DIV>
<DIV CLASS="infoText"><BR></DIV>
<DIV CLASS="infoHeader"><SPAN>PHYSICIAN PAYMENTS SUNSHINE ACT</SPAN></DIV>
<DIV CLASS="infoText"><SPAN>Please note: The Physician Payments Sunshine Act was enacted by Congress to increase public awareness of financial relationships between drug and medical device manufacturers and physicians. In compliance with the requirements of this Act, the commercial supporter/s of this activity may require the Johns Hopkins University School of Medicine to report certain professional information (such as name, address, National Provider Identifier, and State License #) of physician attendees who receive complimentary food and beverage in conjunction with a CME activity. The commercial supporter is required to submit the collected data to the Centers for Medicare and Medicaid Services which will then publish the data on its website.</SPAN><SPAN><SPAN></SPAN></SPAN></DIV>
<DIV CLASS="infoText"><BR></DIV>
<DIV CLASS="infoText"><BR></DIV>
<DIV CLASS="infoText"><SPAN>AMERICANS WITH DISABILITIES ACT (ADA)</SPAN></DIV>
<DIV CLASS="infoText"><SPAN>The Johns Hopkins University School of Medicine and AS<I>i</I>M fully complies with the legal requirements of the ADA and the rules and regulations thereof.</SPAN></DIV>
<DIV CLASS="infoText"><BR></DIV>
<DIV CLASS="infoText"><BR></DIV>
<DIV CLASS="infoHeader"><SPAN>FEE INFORMATION</SPAN></DIV>
<DIV CLASS="infoText"><SPAN>There is no fee for this educational activity. </SPAN></DIV>

A NEW ERA IN TREATING HEMOPHILIA A AND B

More events from HemoAB Symposium

Follow organizers to get events picked for you

A NEW ERA IN TREATING HEMOPHILIA A AND B

More events from HemoAB Symposium

Follow organizers to get events picked for you

You might also like...

Browse more events with different dates, prices, and formats to find your next great experience.